Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

Trial Details

NCT ID
NCT07291037
Phase
PHASE3
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Datopotamab deruxtecan (Dato-DXd)
  • Docetaxel
Locations (sample)
  • Chandler, Arizona, United States|33.30616,-111.84125
  • Duarte, California, United States|34.13945,-117.97729
  • Loma Linda, California, United States|34.04835,-117.26115
  • Grand Junction, Colorado, United States|39.06387,-108.55065
  • Newark, Delaware, United States|39.68372,-75.74966

Key Eligibility Criteria

  • Pathologically documented Stage IIIB, IIIC, or Stage IV non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA…
  • Participants must have documented negative test results for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS prot…
  • Has no known tumour genomic alterations in neurotrophic tyrosine receptor kinase (NTRK), proto-oncogene B-raf (BRAF), rearranged during transfectio…
  • Prospectively assessed trophoblast cell surface protein 2 (TROP2) normalised membrane ratio (NMR) positive.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →